Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.52 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.52 |
| ▸ | F2R | P25116 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31329492 | 1.00 | MEN1 (0.72) | MEN1KMT2AALDH1A1POLBRAB9A | |
| SCHEMBL8088822 | 0.87 | MEN1 (0.72) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL2238394 | 0.86 | MEN1 (0.77) | MEN1KMT2AALDH1A1POLBRAB9A | |
| SCHEMBL11666543 | 0.83 | MEN1 (0.67) | MEN1KMT2AALDH1A1POLBRAB9A | |
| SCHEMBL4188909 | 0.81 | NLRP3 (0.59) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL29720309 | 0.81 | NLRP3 (0.59) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL9373685 | 0.81 | KMT2A (0.62) | MEN1KMT2AALDH1A1POLBRAB9A | |
| SCHEMBL7968814 | 0.81 | MEN1 (0.79) | MEN1KMT2AALDH1A1POLBRAB9A | |
| SCHEMBL7647093 | 0.81 | MEN1 (0.79) | MEN1KMT2AALDH1A1POLBRAB9A | |
| SCHEMBL29128631 | 0.81 | KMT2A (0.63) | MEN1KMT2APOLBRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129046-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-04-24 | — | — | US | disclosed |
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| US-12162855-B2 | Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-12-10 | — | — | US | disclosed |
| EP-3212630-B1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-05-18 | — | — | EP | disclosed |
| EP-3212630-B1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-05-18 | — | — | EP | disclosed |
| EP-3830079-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | The Trustees of Princeton University (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20210155602-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210155602-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-05-27 | — | — | US | disclosed |
| CN-112638881-A | Tetrahydroquinoline derivatives for the treatment of metastatic and chemotherapy-resistant cancers | 普林斯顿大学托管委员会 | 2021-04-09 | — | — | CN | disclosed |
| CN-107531690-B | 4,5,6, 7-tetrahydro-1H-pyrazolo [4,3-c ] pyridin-3-amine compounds as CBP and/or EP300 inhibitors | 基因泰克公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20120220589-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220589-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220589-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012094462-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-07-12 | — | — | WO | disclosed |
| WO-2012094462-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-07-12 | — | — | WO | disclosed |
| WO-2009106534-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106534-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| EP-0162776-B1 | HETEROCYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS USEFUL AS ALDOSE REDUCTASE INHIBITORS CONTAINING THEM | LABORATOIRES UPSA (FR) | 1989-04-19 | — | — | EP | disclosed |
| US-4755509-A | Heterocyclic aldose reductase inhibitors and methods of using them | Carbipem (FR) | 1988-07-05 | — | — | US | disclosed |
| EP-0162776-A2 | Heterocyclic derivatives, process for their preparation and medicaments useful as aldose reductase inhibitors containing them | LABORATOIRES UPSA (FR) | 1985-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155602-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | ALDH3A1, ALDH1A3, ALDH2 | MEN1 3994/4885KMT2A 1640/4885ALDH1A1 4/4885 |
| US-20120220589-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | MEN1 3040/4885KMT2A 3661/4885ALDH1A1 3714/4885 |
| US-20250129046-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | ALDH3A1, ALDH1A1, ALDH2 | MEN1 3567/4885KMT2A 1260/4885ALDH1A1 2/4885 |
| US-12162855-B2 | Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers | ALDH3A1, ALDH2, ALDH1A1 | MEN1 3634/4885KMT2A 1643/4885ALDH1A1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.